Overview

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

Status:
Completed

Trial end date:
2017-08-04

Target enrollment:

Participant gender:

Summary

A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)

Details

Lead Sponsor:

Astellas Scientific & Medical Affairs, Inc.

Treatments:

Mirabegron
Muscarinic Antagonists
Oxybutynin